CSIMarket
 


Novavax inc  (NVAX)
Other Ticker:  
 

Cumulative Novavax Inc's Working Capital Ratio for Trailing Twelve Months Period

NVAX's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

NVAX Working Capital Ratio for Trailing Twelve Months Period

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Growth -33.53 % -11.95 % -25.97 % -15.13 % 2.91 %
Y / Y Current Assets Growth -32.85 % -42.8 % -47.21 % -58.63 % -20.96 %
Working Capital Ratio for Trailing Twelve Months Period 0.64 0.65 0.73 0.8 0.93
Total Ranking # 2168 # 3380 # 3483 # 3597 # 3993
Seq. Current Liabilities Growth 11.34 % -8 % -16.81 % -22 % 47.48 %
Seq. Current Assets Growth 13.62 % -10.71 % 16.12 % -42.99 % -3.21 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2023
On the trailing twelve months basis Despite year on year decrease in Novavax Inc's average Current Liabilities to $1,635 millions, Working Capital Ratio for Trailing Twelve Months Period to 0.64 below company average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 65 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Novavax Inc. While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about NVAX
Working Capital Ratio NVAX in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 66
Sector # 450
S&P 500 # 2134


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
10.29 4.84 0.64
(Sep. 30, 2015)   (Dec 31 2023)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Working Capital Ratio for Trailing Twelve Months Period
Gilead Sciences Inc   1.76 
Lexeo Therapeutics Inc   1.69 
Greenlight Biosciences Holdings Pbc  1.63 
Valneva Se  1.61 
Coeptis Therapeutics Holdings Inc   1.61 
Estrella Immunopharma Inc   1.60 
Protalix Biotherapeutics inc   1.59 
Champions Oncology Inc   1.59 
Cargo Therapeutics Inc   1.54 
Axcella Health Inc   1.35 
Elutia inc   1.34 
Mink Therapeutics Inc   1.24 
Cyclo Therapeutics Inc   1.18 
Biocardia Inc  1.15 
Taysha Gene Therapies Inc   1.14 
Phoenix Biotech Acquisition Corp   1.10 
Outlook Therapeutics Inc   1.10 
Sab Biotherapeutics Inc   1.06 
Agenus Inc  0.94 
Ladrx Corporation  0.91 
Tc Biopharm holdings Plc  0.81 
Mesoblast Ltd  0.75 
Novavax inc  0.64 
Immunitybio inc   0.63 
Aceragen Inc   0.60 
Zeo Scientifix Inc   0.58 
Calidi Biotherapeutics Inc   0.52 
Eloxx Pharmaceuticals Inc   0.49 
Apeiron Capital Investment Corp   0.49 
Zivo Bioscience Inc   0.49 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com